Shares of Fulcrum Therapeutics, Inc. (FULC) plunged 61.1% on Sept. 12 after the company announced disappointing top-line data from the phase III REACH study, which evaluated its pipeline candidate, losmapimod, for treating patients with facioscapulohumeral muscular dystrophy (FSHD), a rare and debilitating disease. Currently, there are no treatments approved for the given indication. The study did not meet its primary endpoint as treatment with losmapimod failed to demonstrate a change from baseline in rela ...

Core Insights - Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases [2] - The company will participate in investor meetings at the Wells Fargo Healthcare Conference on September 4, 2024, and the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024 [1] Company Overview - Fulcrum Therapeutics specializes in small molecules aimed at improving the lives of patients with rare diseases that have high unmet medical needs [2] - The company's lead programs include losmapimod for facioscapulohumeral muscular dystrophy (FSHD) and pociredir for sickle cell disease (SCD) [2] - Fulcrum employs proprietary technology to identify drug targets that can modulate gene expression, addressing the root causes of gene mis-expression [2]

Core Viewpoint - Fulcrum Therapeutics, Inc. (FULC) shows significant upside potential with a mean price target of $16.11, indicating a 71% increase from the current trading price of $9.42 [1] Price Target Analysis - The mean estimate consists of nine short-term price targets with a standard deviation of $5.78, suggesting variability in analyst predictions [2] - The lowest estimate is $5, indicating a potential decline of 46.9%, while the highest estimate is $26, suggesting a potential increase of 176% [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction [7] Analyst Sentiment - Analysts exhibit growing optimism regarding FULC's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [9] - The Zacks Consensus Estimate for the current year has increased by 61.7% over the past month, with five estimates rising and no negative revisions [10] - FULC holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] Caution on Price Targets - While price targets are commonly referenced by investors, they can often mislead and should not be the sole basis for investment decisions [5][8] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-4839948 (State or other juri ...

• Cash Position: As of June 30, 2024, cash, cash equivalents, and marketable securities were $273.8 million, as compared to $236.2 million as of December 31, 2023. The increase in our cash position is due to the $80.0 million upfront payment received from Sanofi in the second quarter of 2024, partially offset by cash used to fund our operating activities in 2024. • Collaboration Revenue: Collaboration revenue was $80.0 million for the three months ended June 30, 2024, as compared to $0.9 million for the thr ...

― Conference call and webcast scheduled for 8:00 a.m. ET today ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) by the end of October 2024 ― CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today reported financial results for ...

Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company's website at www.fulcrumtx.com or by clicking here. Following the live webcast, an archived replay will also be available. Contact: Chris Calabrese LifeSci Advisors, LLC ccalabrese@lifesciadvisors.com 917-680-5608 CAMBRIDGE, Mass. ...

Company Overview - Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules aimed at improving the lives of patients with genetically defined rare diseases [3] - The company has two lead programs in clinical development: losmapimod for facioscapulohumeral muscular dystrophy (FSHD) and pociredir for sickle cell disease (SCD) and other hemoglobinopathies [3] - Fulcrum employs proprietary technology to identify drug targets that can modulate gene expression to address the root causes of gene mis-expression [3] Financial Results Announcement - Fulcrum Therapeutics will release its second quarter 2024 financial results on July 31, 2024, before the U.S. financial markets open [2] - Management will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the results and provide updates on recent corporate developments [2]

Company Overview - Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases with high unmet medical needs [2][3] - The company's lead programs include losmapimod for facioscapulohumeral muscular dystrophy (FSHD) and pociredir for sickle cell disease (SCD) and other hemoglobinopathies [2][3] Upcoming Presentations - Fulcrum Therapeutics announced upcoming presentations at the 31st Annual FSHD Society International Research Congress on June 13-14, 2024, in Denver, Colorado [3] - Presentations will include an abstract on the baseline characteristics of patients in the Phase 3 REACH trial of losmapimod in FSHD [3] Research Focus - The company utilizes proprietary technology to identify drug targets that can modulate gene expression to address the root causes of gene mis-expression [2]

Core Viewpoint - Fulcrum Therapeutics, Inc. (FULC) shows potential for significant upside, with a mean price target of $13.38 indicating a 69.2% increase from the current price of $7.91 [1] Price Targets and Analyst Consensus - The average price target consists of eight estimates ranging from a low of $5 to a high of $19, with a standard deviation of $5.13, indicating variability in analyst predictions [2] - The lowest estimate suggests a decline of 36.8%, while the highest indicates a potential upside of 140.2% [2] - A low standard deviation signifies greater agreement among analysts regarding price movement, which can be a starting point for further research [8] Earnings Estimates and Analyst Optimism - Analysts are optimistic about FULC's earnings prospects, as indicated by a trend of upward revisions in earnings estimates, which historically correlates with stock price movements [10] - Over the past 30 days, the Zacks Consensus Estimate for the current year has increased by 0.5%, with one estimate moving higher and no negative revisions [11] - FULC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for near-term upside [12]